Follow
Debra Van Egeren
Debra Van Egeren
Postdoc, Stanford University School of Medicine
Verified email at stanford.edu
Title
Cited by
Cited by
Year
Structure-based programming of lymph-node targeting in molecular vaccines
H Liu, KD Moynihan, Y Zheng, GL Szeto, AV Li, B Huang, DS Van Egeren, ...
Nature 507 (7493), 519-522, 2014
9002014
Reconstructing the lineage histories and differentiation trajectories of individual cancer cells in myeloproliferative neoplasms
D Van Egeren, J Escabi, M Nguyen, S Liu, CR Reilly, S Patel, B Kamaz, ...
Cell stem cell 28 (3), 514-523. e9, 2021
1612021
Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines
GL Szeto, D Van Egeren, H Worku, A Sharei, B Alejandro, C Park, K Frew, ...
Scientific reports 5 (1), 10276, 2015
1002015
Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein
D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, M Rogers, ...
PloS one 16 (4), e0250780, 2021
692021
Individually optimal choices can be collectively disastrous in COVID-19 disease control
M Stoddard, D Van Egeren, KE Johnson, S Rao, J Furgeson, DE White, ...
BMC public health 21, 1-12, 2021
29*2021
Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure
D Van Egeren, A Novokhodko, M Stoddard, U Tran, B Zetter, MS Rogers, ...
Scientific reports 11 (1), 22630, 2021
212021
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms
D Van Egeren, B Kamaz, S Liu, M Nguyen, CR Reilly, M Kalyva, ...
Experimental hematology 107, 14-19, 2022
162022
Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis
D Van Egeren, M Stoddard, A Novokhodko, MS Rogers, ...
PloS one 16 (11), e0258997, 2021
13*2021
Vaccines alone cannot slow the evolution of SARS-CoV-2
D Van Egeren, M Stoddard, LF White, NS Hochberg, MS Rogers, B Zetter, ...
Vaccines 11 (4), 853, 2023
92023
Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys
D Van Egeren, T Madsen, F Michor
Communications biology 1 (1), 151, 2018
82018
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis
D Van Egeren, K Kohli, JL Warner, PL Bedard, G Riely, E Lepisto, ...
Scientific Reports 12 (1), 19055, 2022
42022
No magic bullet: limiting in-school transmission in the face of variable SARS-CoV-2 viral loads
D Van Egeren, M Stoddard, A Malakar, D Ghosh, A Acharya, S Mainuddin, ...
Frontiers in Public Health 10, 2022
32022
Endemicity is not a victory: the unmitigated downside risks of widespread SARS-CoV-2 transmission
M Stoddard, A Novokhodko, S Sarkar, D Van Egeren, LF White, ...
COVID 2 (12), 1689-1709, 2022
32022
Looking under the lamp-post: quantifying the performance of contact tracing in the United States during the SARS-CoV-2 pandemic
H Bayly, M Stoddard, D Van Egeren, EJ Murray, J Raifman, A Chakravarty, ...
BMC Public Health 24 (1), 595, 2024
22024
The gray swan: model-based assessment of the risk of sudden failure of hybrid immunity to SARS-CoV-2
M Stoddard, L Yuan, S Sarkar, D Van Egeren, LF White, A Chakravarty
medRxiv, 2023.02. 26.23286471, 2023
22023
The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysis
M Stoddard, L Yuan, S Sarkar, D van Egeren, S Mangalaganesh, ...
medRxiv, 2023.01. 26.23285076, 2023
22023
Shielding under endemic SARS-CoV-2 conditions is easier said than done: a model-based analysis
M Stoddard, L Yuan, S Sarkar, M Mazewski, D van Egeren, ...
medRxiv, 2023.01. 22.23284884, 2023
22023
Pathways to altered virulence of SARS-CoV-2
LF White, D Van Egeren, M Stoddard, N D'Angelo, H Bayly, M Sagar, ...
OSF, 2023
12023
Using game theory to investigate the therapeutic potential of disrupting tumor-microenvironment interactions
D Van Egeren, A Chen, M Stoddard, L Yuan, A Chakravarty
Cancer Research 84 (6_Supplement), 7378-7378, 2024
2024
Model-derived progression-free survival (mPFS): A better metric for patient-derived xenograft studies
A Chen, M Stoddard, L Yuan, D Van Egeren, A Chakravarty, D Bottino
Cancer Research 84 (6_Supplement), 6904-6904, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20